The Pfizer and BioNTech coronavirus vaccine has been found to be 100% effective at protecting against COVID-19 in a U.S. trial of 2,260 children between the ages of 12 and 15.
According to Pfizer CEO Albert Bourla, the companies plan to submit clinical trial data to the FDA in hopes that vaccinations will be made available for adolescents before the start of next school year. The data will also be sent to the European Medicines Agency (EMA) for emergency use authorization.
"Across the globe, we are longing for a normal life. This is especially true for our children," said CEO and co-founder of BioNTech Ugur Sahin. "The initial results we have seen in the adolescent studies suggest that children are particularly well protected by vaccination, which is very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant."
The results of the vaccines showed "100% efficacy and robust antibody responses" while achieving better results than a previous study conducted on 16-25 year olds.
The first doses were also administered last week in a trial of children ages six months to 11 years.